Výsledky vyhľadávania - "Pneumothorax/therapy"

  1. 1
  2. 2
  3. 3
  4. 4

    Zdroj: Infection

  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Prispievatelia: In-Kyu Park Kyung Young Chung Chang Young Lee a ďalší

    Zdroj: Annals of Thoracic and Cardiovascular Surgery. 19:6-11

  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    Zdroj: GMS German Medical Science; VOL: 5; DOC06 /20070903/

    Relation: Aitken DR, Minton JP. The "pinch-off sign": a warning of impending problems with permanent subclavian catheters. Am J Surg. 1984;148(5):633-6.; Barrios CH, Zuke JE, Blaes B, Hirsch JD, Lyss AP. Evaluation of an implantable venous access system in a general oncology population. Oncology. 1992;49(6):474-8.; Biffi R, De Braud F, Orsi F, Pozzi S, Arnaldi P, Goldhirsch A, Rotmensz N, Robertson C, Bellomi M, Andreoni B. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer. 2001;92(5):1204-12.; Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, Mahendra P, Baglin T, Marcus R. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol. 1998;101(3):483-6.; Brothers TE, Von Moll LK, Niederhuber JE, Roberts JA, Walker-Andrews S, Ensminger WD. Experience with subcutaneous infusion ports in three hundred patients. Surg Gynecol Obstet. 1988;166(4):295-301.; De Gregorio MA, Miguelena JM, Fernandez JA, de Gregorio C, Tres A, Alfonso ER. Subcutaneous ports in the radiology suite: an effective and safe procedure for care in cancer patients. Eur Radiol. 1996;6(5):748-52.; Foley MJ. Radiologic placement of long-term central venous peripheral access system ports (PAS Port): results in 150 patients. J Vasc Interv Radiol. 1995;6(2):255-62.; Hall P, Cedermark B, Swedenborg J. Implantable catheter system for long-term intravenous chemotherapy. J Surg Oncol. 1989;41(1):39-41.; Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J. 2002;32(3):84-8.; Hiller E. Venöse Thromboembolien bei Tumorpatienten. Prophylaxe und Therapie. Arzneimitteltherapie. 2006;24:35-42.; Hinke DH, Zandt-Stastny DA, Goodman LR, Quebbeman EJ, Krzywda EA, Andris DA. Pinch-off syndrome: a complication of implantable subclavian venous access devices. Radiology. 1990;177(2):353-6.; Hofmann HAF. Ports, Pumpen und Katheter: Artikel über Portimplantationen für das KV-Heft [letter]. Berlin; 2004. Available from: http://www.dr-hofmann-chirurgie.de/20026/presse/20026_presse_kv.pdf; Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8(4):381-8.; Kawasaki R, Morita S, Hisa N, Tsuji A, Noda Y. [Evaluation of 389 cases with a central venous access device inserted peripherally in the forearm]. Gan To Kagaku Ryoho. 1999;26(13):2055-60.; Kock HJ, Pietsch M, Krause U, Wilke H, Eigler FW. Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg. 1998;22(1):12-6.; Laffer U, Durig M, Bloch HR, Zuber M, Stoll HR. Implantierbare Kathetersysteme. Erfahrungen mit 205 Patienten. Dtsch Med Wochenschr. 1989;114(17):655-8.; Ledgerwood AM, Saxe JM, Lucas CE. Venous access devices: a review. Surg Annu. 1993;25 Pt 2:45-57.; Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, Julian JA. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24(9):1404-8.; Lersch C, Eckel F, Sader R, Paschalidis M, Zeilhofer F, Schulte-Frohlinde E, Theiss W. Initial experience with Healthport miniMax® and other peripheral arm ports in patients with advanced gastrointestinal malignancy. Oncology. 1999;57(4):269-75.; Lersch C, Kotowa W, Fung S, Janssen D. Prophylaxis of port system-associated thromboses in advanced oncology patients using heparin flushing. J Cancer Res Clin Oncol. 2004;130(4):235-41.; Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-91.; Linder LE, Curelaru I, Gustavsson B, Hansson HA, Stenqvist O, Wojciechowski J. Material thrombogenicity in central venous catheterization: a comparison between soft, antebrachial catheters of silicone elastomer and polyurethane. JPEN J Parenter Enteral Nutr. 1984;8(4):399-406.; Lokich JJ, Bothe A Jr, Benotti P, Moore C. Complications and management of implanted venous access catheters. J Clin Oncol. 1985;3(5):710-7.; Masci G, Magagnoli M, Zucali PA, Castagna L, Carnaghi C, Sarina B, Pedicini V,Fallini M, Santoro A. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol. 2003;21(4):736-9.; Monreal M, Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol. 2001;106(1-2):69-72.; Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 1996;75(2):251-3.; Nanninga AG, de Vries EG, Willemse PH, Oosterhuis BE, Sleijfer DT, Hoekstra HJ, Mulder NH. Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port. Eur J Cancer. 1991;27(2):147-9.; Pettengell R, Davies AJ, Harvey VJ. Experience with an implantable venous access system for chemotherapy. N Z Med J. 1991;104(915):284-5.; Poorter RL, Lauw FN, Bemelman WA, Bakker PJ, Taat CW, Veenhof CH. Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. Eur J Cancer. 1996;32A(13):2262-6.; Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996;14(10):2731-7.; Rauthe G, Altmann C. Complications in connection with venous port systems: prevention and therapy. Eur J Surg Oncol. 1998;24(3):192-9.; Reichardt P, Kretzschmar A, Biakhov M, Irwin D, Slabber C, Miller L, Bowden C. A phase III randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, fragmin) in preventing catheter-related complications (CRCs) in cancer patients with central venous catheters (CVCs). Proc Am Soc Clin Oncol. 2002;21:abstr 1474.; Salem RR, Ward BA, Ravikumar TS. A new peripherally implanted subcutaneous permanent central venous access device for patients requiring chemotherapy. J Clin Oncol. 1993;11(11):2181-5.; Schauer V, Weiss W, Pickel P, Berger H. Peripher-venöse Portimplantation: Ergebnisse einer prospektiv kontrollierten Studie. RoeFo. 2002:VO45.3.; Starkhammar H, Bengtsson M, Morales O. Fibrin sleeve formation after long term brachial catheterisation with an implantable port device. A prospective venographic study. Eur J Surg. 1992;158(9):481-4.; Stein M, Wagner RH. Komplikationen zentralvenöser Portsysteme: Erfahrungsbericht über 2359 Implantationen. Dtsch Med Wochenschr. 2005;130(18):1129-32.; Torramade JR, Cienfuegos JA, Hernandez JL, Pardo F, Benito C, Gonzalez J,Balen E, de Villa V. The complications of central venous access systems: a study of 218 patients. Eur J Surg. 1993;159(6-7):323-7.; Ulrich S, Taverna C, Bächli E. Thromboseprophylaxe bei Patienten mit implantiertem Port-A-Cath - was tun? Eine nicht durchgeführte Studie. Schweiz Med Forum. 2004;4:562-4.; http://www.egms.de/en/journals/gms/2007-5/000042.shtml

  19. 19
  20. 20